Pfizer Inc. agreed on Thursday to acquire biopharmaceutical company Vicuron Pharmaceuticals Inc. for $1.9 billion in cash, the companies announced.
Under the merger agreement, Pfizer would purchase outstanding Vicuron stock at $29.10 per share, an 84 percent premium over its closing price on Wednesday and a 74 percent premium to the stock’s three-month average closing price.
The deal gives New York-based Pfizer two products under review for approval by the U.S. Food and Drug Administration: anidulafungin for fungal infections and dalbavancin for skin and soft tissue infections.
